Nano-X (NNOX) marketing chief details option and share holdings

Rhea-AI Filing Summary

Nano-X Imaging Ltd. executive Aharon Cohen Tamar, EVP & Chief Marketing Officer, reported his initial equity holdings. He directly holds ordinary shares, including 39,474 ordinary shares, and has 20,000 ordinary shares tied to restricted share units granted on February 5, 2026, which vest 50% after 12 months and 50% after 24 months.

He also holds stock options over ordinary shares: 33,000 at an exercise price of $49.68 expiring on January 18, 2031, 17,000 at $17.63 expiring on March 28, 2032, 8,000 at $17.63 expiring on May 16, 2032, and 55,000 at $11.52 expiring on May 23, 2033. The 2021 grant is fully vested, while the 2022 and 2023 grants vest in 16 equal quarterly installments.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Aharon Cohen Tamar

(Last) (First) (Middle)

C/O NANO-X IMAGING LTD., OFER TECH PARK

94 SHLOMO SHMELTZER ROAD

(Street)

PETACH TIKVA 4970602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nano-X Imaging Ltd. [ NNOX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Marketing Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	20,000	D
Ordinary shares(1)	39,474	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	(2)	01/18/2031	Ordinary shares	33,000	$49.68	D
Stock Option (right to buy ordinary shares)	(3)	03/28/2032	Ordinary shares	17,000	$17.63	D
Stock Option (right to buy ordinary shares)	(4)	05/16/2032	Ordinary shares	8,000	$17.63	D
Stock Option (right to buy ordinary shares)	(5)	05/23/2033	Ordinary shares	55,000	$11.52	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying restricted share units that were granted to the Reporting Person on February 5, 2026, of which 50% vest on the 12-month anniversary of the grant date and the remaining 50% vest on the 24-month anniversary of the grant date.

2. The options reported in this row were granted to the Reporting Person by the Issuer on January 18, 2021 and are fully vested and exercisable as of the date of this report.

3. The options reported in this row were granted to the Reporting Person by the Issuer on March 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (March 28, 2026).

4. The options reported in this row were granted to the Reporting Person by the Issuer on May 16, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (May 16, 2026).

5. The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of the grant date (May 23, 2027).

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ Marina Gofman Feler, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Nano-X (NNOX) Form 3 filing for Aharon Cohen Tamar show?

The Form 3 shows EVP & Chief Marketing Officer Aharon Cohen Tamar’s initial ownership. He holds ordinary shares, restricted share units granted on February 5, 2026, and multiple stock option grants with different exercise prices and expiration dates, all reported as directly owned positions.

How many Nano-X (NNOX) ordinary shares does Aharon Cohen Tamar directly hold?

He directly holds 39,474 ordinary shares. In addition, 20,000 ordinary shares are subject to restricted share units that were granted on February 5, 2026, vesting 50% on the 12‑month anniversary and 50% on the 24‑month anniversary of the grant date.

What stock options over Nano-X (NNOX) shares does Aharon Cohen Tamar report?

He reports options over 33,000 ordinary shares at $49.68 expiring January 18, 2031; 17,000 at $17.63 expiring March 28, 2032; 8,000 at $17.63 expiring May 16, 2032; and 55,000 at $11.52 expiring May 23, 2033, all held directly.

How do Aharon Cohen Tamar’s Nano-X (NNOX) restricted share units vest?

Restricted share units over 20,000 ordinary shares were granted on February 5, 2026. According to the disclosure, 50% vest on the 12‑month anniversary of the grant date and the remaining 50% vest on the 24‑month anniversary, creating a two‑year vesting schedule.

What are the vesting terms of Aharon Cohen Tamar’s Nano-X (NNOX) option grants?

The January 18, 2021 option grant is fully vested and exercisable. The March 28, 2022, May 16, 2022, and May 23, 2023 grants vest in 16 equal quarterly installments of 6.25% each, becoming fully exercisable on the four‑year anniversaries of their respective grant dates.

Is Aharon Cohen Tamar’s Nano-X (NNOX) Form 3 a record of trades or holdings?

This Form 3 functions as an initial statement of beneficial ownership. The entries are categorized as holdings, with no buy or sell transactions reported, listing his existing ordinary shares, restricted share units, and stock option positions with their key terms.